Treatment of hepatitis C virus infection in patients with end-stage renal disease.
about
KASL clinical practice guidelines: management of hepatitis CHepatitis C in non-hepatic solid organ transplant candidates and recipients: A new horizonHepatitis C infection in hemodialysis patients: A reviewHepatitis C Therapy in Renal Patients: Who, How, When?Nanomedicines in the treatment of hepatitis C virus infection in Asian patients: optimizing use of peginterferon alfa.Potential Hepatoprotective Role of Galectin-3 during HCV Infection in End-Stage Renal Disease Patients.Sofosbuvir Use in the Setting of End-stage Renal Disease: A Single Center Experience.Transient elastography to assess hepatic fibrosis in hemodialysis chronic hepatitis C patients.Management of patients with hepatitis C infection and renal disease.Hepatitis C in hemodialysis patientsTreatment of HCV patients before and after renal transplantation.Pharmaceutical management of hepatitis B and C in liver and kidney transplant recipients.Interferon-Based Treatment of Hepatitis C Virus Infection Reduces All-Cause Mortality in Patients With End-Stage Renal Disease: An 8-Year Nationwide Cohort Study in Taiwan.Critical review of the use of erythropoietin in the treatment of anaemia during therapy for chronic hepatitis C.APASL consensus statements and management algorithms for hepatitis C virus infection.Interferon treatment for patients with chronic hepatitis C complicated with chronic renal failure receiving hemodialysis.Treatment of HCV in Renal Disease: Subtle Management Considerations in the Era of Direct-acting Antivirals.Hepatitis C Virus Infection in Patients with End-Stage Renal Disease: A Study from a Tertiary Care Centre in India.Safety and efficacy of dual direct-acting antiviral therapy (daclatasvir and asunaprevir) for chronic hepatitis C virus genotype 1 infection in patients on hemodialysis.Efficacy and safety of sofosbuvir and daclatasvir in treatment of kidney transplantation recipients with hepatitis C virus infection.Multicenter study of pegylated interferon α-2a monotherapy for hepatitis C virus-infected patients on hemodialysis: REACH study.Peginterferon alfa-2a with or without low-dose ribavirin for treatment-naive patients with hepatitis C virus genotype 2 receiving haemodialysis: a randomised trial.Usefulness of combined application of double-filtration plasmapheresis and twice-daily injections of interferon-β in hemodialysis patients with hepatitis C virus genotype 1b infection and a high viral load.Virological responses of pegylated interferon alpha-2a treatment in hemodialysis patients infected with hepatitis C.Outcome of HCV genotype 1 treatment in HIV-coinfected patients with chronic kidney disease.Characteristics and Prognosis of Hepatocellular Carcinoma in Japanese Patients Undergoing Dialysis.KASL clinical practice guidelines: management of hepatitis C.2017 KASL clinical practice guidelines management of hepatitis C: Treatment of chronic hepatitis C
P2860
Q26752471-19840352-573C-4668-973E-6EC08FDA726AQ26773201-AAF279A7-B5E2-4479-BF06-758BDCE8EE2FQ27009100-74FC1D31-2091-48C9-A7A4-7BE9622DF876Q28077130-ECFBC402-D9C1-4D6B-8C68-D27A883432C2Q33559298-452B2B4E-9F2B-4DF9-A1A6-76F26CE39C1BQ33604689-CB5D5DCE-06B6-4742-8956-B3920BD97A6AQ33621619-E555B18F-B13F-4F9E-BAF0-720FF67B41A8Q34926896-C4C9A13C-3405-4DE0-AEA7-25D2C1F2A8D4Q35127041-DB772B8D-EA05-421E-B7CB-14C251DDCBDFQ35237329-8CF09B83-2733-4A16-AB85-425792A43656Q35714749-B56505F5-D86B-450B-AA3C-AF2A0BE34D1EQ36254143-08DB7650-F9B6-448B-B837-293C2AA82569Q37328650-A6CEDCD0-1AC5-40DE-8AFC-CE7FAE483B78Q37975253-46CF8971-577C-4C0B-868E-A8B6E11F86CDQ38552131-462E8CD1-5357-49E4-84C1-82ED8F0F50AAQ39488889-CEDE37BE-956C-468D-9316-0DA20DE202EDQ40171525-3C374D00-80FB-4280-8142-1E3D861E979DQ40668424-50700416-7C5C-44FC-93C3-8771C76EC99DQ40793177-7246809C-CAE0-4A90-A48F-190F875FDF7CQ41608541-BD5242D4-219E-49D4-8D7F-6265647A7AFEQ41750716-A211ABD4-A6A9-4675-AA9C-F664F75CCC35Q42223532-6BE4CD84-1C4F-4B15-9375-2894CEA3ADB0Q42283790-02681261-F4B5-477C-9E3D-603119797627Q42982413-E976EBFD-FA53-457D-8C25-EE31DC5BCF58Q42985195-A1ACCB89-3753-4B46-B38B-9ADEC04A1721Q48112497-170FAA45-18E4-4E69-9894-1ED3B456B42CQ51836024-BD87D96E-3DD5-4CF4-A4B0-8AD1B987872DQ58788714-571EB376-4BB9-4396-A560-E8FD19714BDE
P2860
Treatment of hepatitis C virus infection in patients with end-stage renal disease.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on February 2011
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Treatment of hepatitis C virus infection in patients with end-stage renal disease.
@en
Treatment of hepatitis C virus infection in patients with end-stage renal disease.
@nl
type
label
Treatment of hepatitis C virus infection in patients with end-stage renal disease.
@en
Treatment of hepatitis C virus infection in patients with end-stage renal disease.
@nl
prefLabel
Treatment of hepatitis C virus infection in patients with end-stage renal disease.
@en
Treatment of hepatitis C virus infection in patients with end-stage renal disease.
@nl
P2860
P1476
Treatment of hepatitis C virus infection in patients with end-stage renal disease
@en
P2093
Chen-Hua Liu
Jia-Horng Kao
P2860
P304
P356
10.1111/J.1440-1746.2010.06488.X
P577
2011-02-01T00:00:00Z